Kornimate/medical-research-clean huggingface dataset:
registry on salvage antiviral treatment for patients experiencing adv and / or cmv reactivation post allogeneic hsct

Conditions: Infectious Complications Following HSCT

Summary: design: disease registry - non-interventional. indication: patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.

in this disease registry, data on approximately 120 allo hsct patients who have received salvage treatment (second or later line) with any antiviral therapy for adv and / or cmv post allogeneic hsct will be documented; of these 120, at least 40 patients will have been treated with cell medica's immune reconstitution act as salvage therapy. the patients will be consented prospectively or retrospectively for collection of data. data will be collected at baseline, 6 months and 1 year after commencement of salvage treatment. retrospective data collection (for patients who underwent hsct in 2010 or later) is permitted.

Eligibility criteria:
1. written informed consent 2. physician requested salvage (defined as refractory to first, requirement for second line or greater) treatment for adv and / or cmv reactivation post allogeneic hsct.

Keywords: adv cmv hsct
omega-3 fatty acid administration in dialysis patients

Conditions: End Stage Renal Disease

Summary: the overall goal of this study is to examine the role of fish oil supplementation in ameliorating the inflammatory state of uremia and the related muscle protein catabolism associated with this disease state. we hypothesize that if administered for a period of 3 months, fish oil will improve the chronic uremic inflammation. we further hypothesize that fish oil administration will improve the muscle protein breakdown associated with uremia and inflammation.


Eligibility criteria:
inclusion criteria: * patients on chd for more than 6 months; * ability to read and sign the consent form; * have acceptable dialysis adequacy (kt/v \> 1.2); * use biocompatible hemodialysis membrane; * have a patent, well functioning, arteriovenous dialysis access or permanent dialysis catheter (no other option for arteriovenous access); * signs of chronic inflammation (average crp of ≥ 5 mg/l for 3 consecutive measurements) exclusion criteria: * pregnancy; * intolerance to the study medication; * severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer, hiv, liver disease); * diabetes mellitus on insulin therapy; * hospitalization within 1 month prior to the study; * malfunctioning arterial-venous vascular access (recirculation and/or blood flow \< 500 ml/min); * patients receiving steroids (\> 5 mg/day) and/or other immunosuppressive agents; * life-expectancy less than 6 months; * age less than 18 years old; * atrial fibrillation (only for those undergoing the optional pulse wave velocity); * hypersensitivity to organic nitrates, isosorbide, or nitroglycerin (only for those undergoing the optional brachial artery doppler).

Keywords: inflammation end stage renal disease
mechanisms of lung defense and their relationship with airway infection in chronic obstructive pulmonary disease (copd)

Conditions: Bacterial Infection in COPD

Summary: study hypothesis: chronic obstructive pulmonary disease (copd) patients with chronic bacterial colonization have lower levels of mucins and antimicrobial peptides in their airways

main objective: (1) to investigate the expression of mucins and antimicrobial peptides in patients with severe copd and their relationship with the presence of bacteria in the airway

Eligibility criteria:
inclusion criteria: * copd exclusion criteria: * acute exacerbation in the last 4 weeks
human fibrinogen concentrate (fgtw) in pediatric patients with congenital fibrinogen deficiency

Conditions: Hypofibrinogenemia, Congenital; Afibrinogenemia, Congenital

Summary: the aim of the study is to evaluate clinical pharmacology, efficacy and safety of fgtw in pediatric patients with congenital fibrinogen deficiency.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent form by parents or a legal representative * age less or equal to 12 years old * patients with inherited afibrinogenemia or severe inherited hypofibrinogenemia * negative results on hcg-based pregnancy test for females of childbearing potential (presence of menstruation) exclusion criteria: * dysfibrinogenemia * acquired fibrinogen deficiency * suspected present or past anticoagulation inhibitor * personal history of venous or arterial thrombosis or thromboembolic event * co-morbidity with other/unrelated coagulopathies * administration of any fibrinogen concentrate or fibrinogen containing blood product during the last 15 days * permanent treatment with antithrombotic or anti-platelet agents such as heparins, anti-iia or anti-xa agents, aspirin, clopidogrel and nsaids.
treatment resistant depression subcallosal cingulate network dbs (transcend)

Conditions: Treatment Resistant Depression

Summary: the goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (sccwm) using deep brain stimulation (dbs) as an adjunctive treatment of non-psychotic unipolar major depressive disorder (mdd) in adults.

the aim of this prospective, multi-centered, double-blind, randomized, delayed-stimulation/ sham-stimulation controlled 12-month study is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (sccwm) using the infinity™ deep brain stimulation (dbs) system as an adjunctive treatment of non-psychotic unipolar major depressive disorder (mdd) for adults who are experiencing a major depressive episode (mde) with inadequate response to 4 or more antidepressant treatments. in a double-blind fashion, half the subjects will receive active dbs therapy, while half will receive sham stimulation. after the 12-month endpoint, all subjects will be unblinded to their treatment group, and subjects in the control arm will receive active dbs therapy.

Eligibility criteria:
* inclusion criteria: 1. the patient must be diagnosed with non-psychotic unipolar major depressive disorder. 2. the patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes. 3. the patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose. 4. depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit * exclusion criteria: 1. pregnant or those who plan to become pregnant during study 2. presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol. 3. current or lifetime history of psychotic features in any major depressive episode. 4. has an intracranial central nervous system disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication. 5. significant acute suicide risk. 6. diagnosis of substance use disorder or alcohol use disorder without sustained remission (12 months or longer). 7. current and ongoing use of neurostimulation treatment that may interfere with dbs therapy/system. 8. treatment with another investigational device or investigational drugs.

Keywords: dbs major depressive disorder bilateral stimulation antidepressant treatment neurostimulation abt-cip-10494
central serous chorioretinopathy: etiology, course and prognosis

Conditions: Central Serous Chorioretinopathy

Summary: pathogenesis of central serous chorioretinopathy is not entirely understood yet, therefore further investigations are needed. during this study patients with an acute episode of central serous chorioretinopathy are observed with established ophthalmologic methods (multimodal imagine) every 6 weeks until subretinal fluid is reabsorbed to gain further insides in etiology, course and prognosis of this disease.

patients with central serous chorioretinopathy are recruited from the department of ophthalmology at the medical university of vienna. all patients undergo etdrs visual acuity measurement, pelli-robson contrast examination, amsler-grid testing, questionnaire testing, ophthalmologic examination, sd-oct and polarization-sensitive oct, fundus autofluorescence, fluorescein angiography, indocyanine-green angiography, fundus photo and microperimetry. patients are re-examined after an interval of 6 weeks until subretinal fluid is entirely reabsorbed to gain further insides in etiology, course and prognosis of this disease.

Eligibility criteria:
inclusion criteria: * signed informed consent form * age over 18 years * acute episode of central serous chorioretinopathy * symptoms for less than two weeks * no treatment on study eye exclusion criteria: * bad compliance * protected patient group (pregnant women)

Keywords: ccs csc subretinal fluid multimodal imaging
usage, usability & effect on adherence and clinical outcomes of text message reminders for adolescents with asthma

Conditions: Asthma

Summary: the purpose of this randomized crossover study is to determine the efficacy of participant designed medication reminders on asthma control, asthma related quality of life,and medication adherence. in addition, this study will provide data regarding the usage, usability, acceptability of an online system designed for creating text message reminders. it is hypothesized that the teens receiving text message reminders will report having greater quality of life related to their asthma, a reported increase in the control of their asthma, and increased adherence to their medication regimen compared to those teens that are not receiving the text message reminders.

adolescents are typically less adept at managing chronic illnesses and adhering to treatment plans than are parents of younger children. adolescents are also typically "early adopters" to technological solutions and text messages are integral in today's teen culture. text messages are gaining acceptance in health care both as appointment reminders and direct inquiries. the purpose of this randomized crossover study is to examine the effect of participant designed medication reminders on asthma control, asthma related quality of life, and medication adherence. in addition, this study will provide data regarding the usage, usability, and acceptability of an online system designed for creating text message reminders.

Eligibility criteria:
inclusion criteria: * between the ages of 12 and 22 * diagnosis of persistent asthma * receiving care at cincinnati children's hospital medical center or affiliate * prescription of a controller medication * must have a cell phone that receives text messages * asthma is not well-controlled based on act score * english speaking exclusion criteria: * no diagnosis of persistent asthma * receiving asthma care other than at a cincinnati children's hospital medical center or affiliate * asthma is well-controlled based on act score * does not have a cell phone that receives text messages or plans to change phones within the next 6 months * is not taking a daily asthma controller medication * is currently receiving asthma appointment or medication reminder text messages from another source
the effect of extended yellow fever vaccine information on symptom reports following vaccination

Conditions: Vaccination

Summary: this study aims to investigate the effect of providing additional information about possible mild side effects of the yellow fever vaccination on the reporting of physical symptoms. additionally, the project aims to investigate the relationship between individual characteristics (trait anxiety and perceived sensitivity to medication) and the reporting of physical symptoms, as well as possible interactions between the level of information provided and individual characteristics. we hypothesize that more information about mild symptoms provided to participants will increase the number of reported symptoms after vaccination.


Eligibility criteria:
inclusion criteria: * receiving yellow fever vaccination * english speaker * aged over 18 exclusion criteria: * no phone for follow-up

Keywords: yellow fever vaccine patient information symptom reports patient satisfaction
wearable biofeedback devices for remote physiotherapy and rehabilitation

Conditions: Arthritis; Fibromyalgia; Chronic Pain

Summary: this study evaluates the effectiveness of wearable biofeedback devices in improving pain, mobility, and rehabilitation outcomes in elderly patients with arthritis and fibromyalgia in karachi, pakistan. in a randomized controlled trial involving 120 participants, one group will use biofeedback-integrated devices with guided exercises and virtual consultations, while the control group receives standard physiotherapy. the results will inform the potential of digital health solutions to improve accessibility and outcomes in remote rehabilitation for chronic pain management.

arthritis and fibromyalgia are common chronic musculoskeletal conditions among the elderly population, contributing to significant pain, reduced mobility, and diminished quality of life. in urban centers like karachi, pakistan, access to consistent and effective physiotherapy is often hindered by mobility limitations and inadequate healthcare infrastructure. this randomized controlled trial (rct) investigates the efficacy of wearable biofeedback devices as an innovative approach to address these challenges. a total of 120 elderly participants diagnosed with arthritis and/or fibromyalgia will be enrolled and randomized into two groups (60 participants per group). the intervention group will receive wearable biofeedback devices that monitor physiological parameters such as heart rate variability (hrv) and provide real-time feedback during guided home-based exercises, complemented by virtual physiotherapy consultations. the control group will follow standard physiotherapy exercise routines without biofeedback or virtual support. primary outcome measures include pain intensity (measured using a standardized pain scale), functional mobility (assessed via timed mobility tests), and joint range of motion. secondary outcomes will assess heart rate variability, patient adherence to exercise protocols, and changes in psychological well-being. this study seeks to determine whether wearable biofeedback can enhance rehabilitation outcomes, promote exercise adherence, and offer a viable, accessible alternative to conventional physiotherapy. if successful, the intervention could transform chronic pain management and rehabilitation strategies for aging populations, especially in resource-constrained urban environments.

Eligibility criteria:
inclusion criteria: elderly adults aged 60-80 years diagnosed with arthritis or fibromyalgia. experiencing moderate to severe pain and mobility limitations. no recent surgical interventions or contraindications for physiotherapy. access to smartphones and internet connectivity for remote monitoring. exclusion criteria: patients with severe cognitive impairments affecting adherence to rehabilitation. presence of comorbidities that contraindicate physiotherapy (e.g., severe cardiac conditions). lack of access to digital devices required for remote monitoring.
itm vs ql for pediatric open lower abdominal procedures

Conditions: Pain Control; Ureteral Reimplantation; Pediatrics; Intrathecal Morphine

Summary: patients between the ages of 12 months and 11 years who are undergoing an open lower abdominal procedure will be randomized to receive intrathecal morphine, or bilateral quadratus lumborum block. the investigators will compare the effect that intrathecal morphine and quadratus lumborum blocks have on the duration of pain control as demonstrated by charted pain scores and morphine equivalents in the first 48 hours. this study will also assess the side effects of each intervention such as nausea and vomiting, and itching.


Eligibility criteria:
inclusion criteria: * ages 12 months to 11 years old * undergoing an open lower abdominal procedure exclusion criteria: * allergy to morphine or amide local anesthetics * localized rash at site of planned regional anesthetic block * bleeding diathesis * spinal dysmorphism * previous spinal surgery with instrumentation of the lumbar spine * inability or unwillingness of parent or legal guardian to give informed consent. * prior enrollment and randomization in this study
comparison of focused eswt by frequency for patients with myofascial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: to investigate the efficacy and safety according to the frequency of focused eswt in patients with myofascial pain syndrome.

myofascial pain syndrome is one of the common causes of musculoskeletal pain seen in clinical practice and is characterized by the presence of trigger points associated with sensitive areas such as taut bands of skeletal muscle. it may also be accompanied by referred pain, which is pain in other parts of the body. although the pathophysiology and etiology of myofascial pain syndrome and trigger points are still unknown, there are reports that myofascial pain is a complex form of neuromuscular dysfunction caused by motor and sensory abnormalities involving both the peripheral nervous system and the central nervous system. recently, it has been considered as a method of treatment for myofascial pain syndrome. in addition, although pain reduction and functional improvement of focused eswt in patients with myofascial pain syndrome have been reported, related studies are lacking on the effect of focused eswt according to the frequency difference. the purpose of the study is to examine the efficacy and safety of focused type eswt frequency in patients with myofascial pain syndrome.

Eligibility criteria:
inclusion criteria: 1. those diagnosed with myofascial pain syndrome according to simon's criteria 2. pain is 4 points or more on the numerical rating scale (nrs) exclusion criteria: 1. pain is due to trauma, fibromyalgia and neurological disorders including neuromyopathy, myelopathy, and stroke 2. if you have received injection treatment for trigger points within the last 2 months or have had surgery on the painful area within 1 year 3. if there is a high risk of bleeding due to severe coagulopathy, etc. or if you have recently had severe bleeding (except taking antiplatelet) 4. if you have a tumor, infection, kidney failure, severe liver disease, epilepsy, skin disease, or mental retardation

Keywords: eswt myofascial pain syndrome
dose escalation and pk study of m2es in subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this study is dose-escalation open-label study to determine the mtd of m2es in subjects with advanced solid tumors the recommended phase ii dose.the recommended dose and regimen of m2es will be selected to perform the pharmacokinetic study profiles.

this study is a phase i dose-escalation open-label study to determine the mtd of m2es in subjects with advanced solid tumors the recommended phase ii dose.the recommended dose and regimen of m2es will be selected to perform the pharmacokinetic study profiles.

Eligibility criteria:
inclusion criteria: 1. 18 to 60 years of age 2. patients had histologically or cytologically confirmed solid tumors that was refractory to standard therapy. 3. life expectancy of at least 3 months. 4. ecogps ≤ 1 5. adequate hematologic, renal, and hepatic function was required as determined by the following: wbc ≥4×109/l, absolute neutrophil count ≥ 1.5×109/l, platelet count ≥100×109/l, hemoglobin ≥ 9g/dl, total bilirubin ≤1.5 upper limit of normal \[uln\],ast ≤ 2.5 uln, or ≤ 5 uln if there was evidence of liver metastases; alkaline phosphatase ≤ 2.5 uln, or ≤ 5 uln if there was evidence of liver metastases; creatinine clearance ≥50 ml/min. exclusion criteria: 1. pregnant and latent women, no contraception for women of childbearing age 2. have taken other treatments 3. be allergic to endostatin and other ingredient 4. gastrointestinal hemorrhage 5. have participated any clinical trail during the last 4 week 6. ecg: qtc ≥ 480 ms 7. patients had clinically apparent cns disease ( primary brain tumors, tumor related apoplexy, cns metastases, carcinomatous meningitis.) 8. cardiovascular and mental disease 9. hiv-1 infected 10. hbv, hbv infected ,hepatitis b surface antigen positive 11. patients on therapeutic doses of heparin or antiplatelet agents.

Keywords: advanced solid tumors
spectroscopy in parkinson disease

Conditions: Parkinson Disease

Summary: the primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic parkinson's disease from healthy controls.

oxidative stress has been implicated as a factor in the pathogenesis of parkinson's disease (pd). the overall goal of this proposal is to use a novel metabolomics platform, based on near infrared biospectroscopy, to detect oxidatively modified blood plasma constituents. these spectral findings can be used to model the degree of oxidative stress with a modeled "stress index" that may distinguish pd cases from healthy elderly controls.

Eligibility criteria:
inclusion criteria: pd subjects: 1. postcept subjects with a diagnosis of pd based on uk brain bank criteria. 2. willing and able to provide informed consent. healthy controls: 1. no current diagnosis or known history of a neurological disease/disorder. 2. non-blood relative of a patient or subject at the site who has diagnosis of pd (may include healthy controls from the probe study). 3. no first degree relatives with diagnosis of pd 4. moca score \> 26. 5. age \> 45. 6. willing and able to provide informed consent.

Keywords: parkinson disease blood plasma metabolomics spectroscopy oxidative stress.
the effect of balance training on neuromuscular control in subjects with cai

Conditions: Ankle Inversion Sprain; Instability, Joint; Treatment; Neuromuscular Control; Reaction Time

Summary: the goal of this study is evaluate the effect of uni-axial versus multidirectional balance training on muscle reaction time in subjects with chronic ankle instability. muscle reaction time is measured on a trapdoor simulating an inversion sprain before and after a 6 week lasting balance training protocol.


Eligibility criteria:
according to the consensus statement of the international ankle consortium inclusion criteria: * history of an ankle sprain * repetitive ankle sprains and feelings of instability and giving way * ankle functionality is documented (not as inclusion criteria) exclusion criteria: * fracture * surgery * equilibrium disorder